Publication | Closed Access

Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis

InflammationNeurobiology Of DiseaseAutoimmune DiseaseLow Dose NaltrexoneNeurological DisorderMedicineImmunologyNeuropharmacologyAutoimmunityBrain-immune InteractionExtended PeriodNeuroscienceNeurologyMultiple SclerosisNeuroimmunologySocial SciencesNeuroinflammation